Fortress Biotech, Inc. (FBIOP)
FBIOP Stock Price Chart
Explore Fortress Biotech, Inc. interactive price chart. Choose custom timeframes to analyze FBIOP price movements and trends.
FBIOP Company Profile
Discover essential business fundamentals and corporate details for Fortress Biotech, Inc. (FBIOP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Nov 2017
Employees
78.00
Website
https://www.fortressbiotech.comCEO
Lindsay A. Rosenwald
Description
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
FBIOP Financial Timeline
Browse a chronological timeline of Fortress Biotech, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 17 Aug 2026
EPS estimate is -$0.20, while revenue estimate is $18.30m.
Earnings released on 14 May 2026
EPS came in at $2.82 surpassing the estimated -$0.22 by +1.38k%, while revenue for the quarter reached $16.04m , missing expectations by -1.84%.
Earnings released on 31 Mar 2026
EPS came in at -$0.15 falling short of the estimated $0.11 by -236.36%, while revenue for the quarter reached $16.08m , missing expectations by -38.55%.
Earnings released on 13 May 2025
EPS came in at -$0.48 surpassing the estimated -$0.50 by +2.89%, while revenue for the quarter reached $13.14m , beating expectations by +13.07%.
Earnings released on 31 Mar 2025
EPS came in at -$0.24 surpassing the estimated -$0.75 by +67.82%, while revenue for the quarter reached $15.12m , missing expectations by -7.22%.
Earnings released on 14 Nov 2024
EPS came in at -$0.65 falling short of the estimated -$0.60 by -9.79%, while revenue for the quarter reached $14.63m , missing expectations by -6.08%.
Earnings released on 13 Aug 2024
EPS came in at -$0.60 surpassing the estimated -$1.22 by +51.14%, while revenue for the quarter reached $14.90m , beating expectations by +0.99%.
Dividend declared on 14 Jun 2024
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Jun 2024.
Earnings released on 15 May 2024
EPS came in at -$0.90 surpassing the estimated -$1.73 by +48.04%, while revenue for the quarter reached $13.03m , missing expectations by -7.79%.
Dividend declared on 14 May 2024
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 May 2024.
Dividend declared on 12 Apr 2024
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Apr 2024.
Earnings released on 28 Mar 2024
EPS came in at -$0.61 surpassing the estimated -$1.65 by +62.63%, while revenue for the quarter reached $19.95m , beating expectations by +31.96%.
Dividend declared on 14 Mar 2024
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Mar 2024.
Dividend declared on 14 Feb 2024
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 29 Feb 2024.
Dividend declared on 11 Jan 2024
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Jan 2024.
Dividend declared on 14 Dec 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Dec 2023.
Dividend declared on 14 Nov 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Nov 2023.
Dividend declared on 12 Oct 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Oct 2023.
Earnings released on 30 Sept 2023
EPS came in at -$0.10 surpassing the estimated -$3.21 by +96.99%, while revenue for the quarter reached $34.75m , beating expectations by +139.65%.
Dividend declared on 14 Sept 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Sept 2023.
Earnings released on 14 Aug 2023
EPS came in at -$0.47 surpassing the estimated -$3.41 by +86.11%, while revenue for the quarter reached $17.39m , beating expectations by +12.44%.
Dividend declared on 14 Aug 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Aug 2023.
Dividend declared on 13 Jul 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Jul 2023.
Dividend declared on 14 Jun 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Jun 2023.
Earnings released on 15 May 2023
EPS came in at -$0.41 , while revenue for the quarter reached $12.43m .
Dividend declared on 12 May 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 May 2023.
Dividend declared on 13 Apr 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Apr 2023.
Earnings released on 31 Mar 2023
EPS came in at -$1.10 , while revenue for the quarter reached $16.40m .
Dividend declared on 14 Mar 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Mar 2023.
Dividend declared on 14 Feb 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 28 Feb 2023.
Dividend declared on 12 Jan 2023
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Jan 2023.
Dividend declared on 14 Dec 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Dec 2022.
Earnings released on 14 Nov 2022
EPS came in at -$0.25 , while revenue for the quarter reached $16.53m .
Dividend declared on 14 Nov 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Nov 2022.
Dividend declared on 13 Oct 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Oct 2022.
Dividend declared on 14 Sept 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Sept 2022.
Dividend declared on 12 Aug 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Aug 2022.
Earnings released on 11 Aug 2022
EPS came in at -$0.24 , while revenue for the quarter reached $18.89m .
Dividend declared on 14 Jul 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Jul 2022.
Dividend declared on 14 Jun 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Jun 2022.
Earnings released on 12 May 2022
EPS came in at -$0.24 , while revenue for the quarter reached $23.93m .
Dividend declared on 12 May 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 May 2022.
Dividend declared on 13 Apr 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Apr 2022.
Earnings released on 28 Mar 2022
EPS came in at -$0.48 , while revenue for the quarter reached $18.28m .
Dividend declared on 14 Mar 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Mar 2022.
Dividend declared on 14 Feb 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 28 Feb 2022.
Dividend declared on 13 Jan 2022
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Jan 2022.
Dividend declared on 14 Dec 2021
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 31 Dec 2021.
Earnings released on 15 Nov 2021
EPS came in at -$0.31 , while revenue for the quarter reached $21.09m .
Dividend declared on 12 Nov 2021
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Nov 2021.
Dividend declared on 14 Oct 2021
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Oct 2021.
Dividend declared on 14 Sept 2021
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Sept 2021.
Earnings released on 16 Aug 2021
EPS came in at -$0.05 , while revenue for the quarter reached $17.84m .
Dividend declared on 12 Aug 2021
A dividend of $0.20 per share was announced, adjusted to $0.20. The dividend was paid on 30 Aug 2021.
FBIOP Stock Performance
Access detailed FBIOP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
